Smith & Nephew plc logo

Smith & Nephew plc (NPW1)

Market Open
10 Aug, 20:00
13. 00
-0.1
-0.7634%
13.21B Market Cap
- P/E Ratio
0.92% Div Yield
0 Volume
- Eps
13.1
Previous Close
Add Transaction
Day Range
12.9 13
Year Range
12.3 16.55
Want to track NPW1 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NPW1 trading today lower at €13, a decrease of -0.7634% from yesterday's close, completing a monthly increase of 2.3622% or €0.3. Over the past 12 months, NPW1 stock lost -7.7032%.
NPW1 pays dividends to its shareholders, with the most recent payment made on May 27, 2026.
The last earnings report, released on Mar 02, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).

NPW1 Chart

People also search for

GE9
GENMAB AS DK 1
266
-0.6721%

Smith & Nephew plc (NPW1) FAQ

What is the stock price today?

The current price is €13.00.

On which exchange is it traded?

Smith & Nephew plc is listed on XHAN.

What is its stock symbol?

The ticker symbol is NPW1.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.92%.

What is its market cap?

As of today, the market cap is 13.21B.

Has Smith & Nephew plc ever had a stock split?

No, there has never been a stock split.

Smith & Nephew plc Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Deepak S. Nath CEO
XHAN Exchange
GB0009223206 ISIN
GB Country
18,362 Employees
1 Oct 2026 Last Dividend
- Last Split
- IPO Date
Smith & Nephew plc is a global medical technology enterprise dedicated to the development, manufacturing, and worldwide commercialization of an extensive array of medical devices. Its product portfolio spans several key areas. In orthopedics, the company provides knee implants for replacement procedures, hip implants for joint reconstruction, and trauma and extremities products, including both internal and external fixation devices, crucial for stabilizing severe fractures and correcting deformities. For sports medicine, Smith & Nephew offers joint repair solutions tailored for surgeons. This includes specialized instruments, advanced technologies, and implants essential for minimally invasive joint surgeries, targeting soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, the firm supplies arthroscopic enabling technologies that enhance surgical visualization and intervention within joints. This suite encompasses fluid management equipment for surgical access, high-definition cameras, digital imaging capture systems, scopes, light sources, and monitors. It also features radiofrequency, electromechanical, and mechanical tissue resection devices, alongside hand instruments for precise tissue removal. The company also provides dedicated ear, nose, and throat (ENT) solutions. Its Advanced Wound Management division delivers comprehensive solutions for the treatment and prevention of acute and chronic wounds, covering conditions like leg, diabetic, and pressure ulcers, burns, and post-operative wounds. This segment includes advanced wound bioactives, comprising biologics and other bioactive technologies for debridement, dermal repair, and regeneration. Regenerative medicine products, such as skin, bone graft, and articular cartilage substitutes, are also offered. Furthermore, Smith & Nephew provides advanced wound devices, including traditional and single-use negative pressure wound therapy systems, and hydrosurgery technology. Primarily serving healthcare providers globally, Smith & Nephew plc was founded in 1856 and is headquartered in Watford, United Kingdom.

Contact Information

Address: Building 5
Phone: 44 1923 477 100